섬유주세포에서 베바시주맙과 라니비주맙이 일산화질소합성효소의 발현에 미치는 영향
Effect of Bevacizumab and Ranibizumab on the Expression of eNOS in Trabecular Meshwork Cells
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
목적: 섬유주세포에서 항혈관내피생성인자인 베바시주맙과 라니비주맙이 eNOS의 발현에 미치는 영향을 비교해 보고자 하였다. 대상과 방법: 사람의 섬유주세포를 일차배양한 후 1% 혈청이 포함된 배지를 이용하여 베바시주맙과 라니비주맙에 0.5 mg/mL의 농도로 각각 30분간 노출시킨 후 RT-PCR을 이용하여 eNOS mRNA의 발현을 조사하였다. 또한 20 ng/mL 혈관내피생성인자와 0.5mg/mL 베바시주맙과 라니비주맙에 각각 노출시킨 후 Griess assay를 이용하여 일산화질소의 생성량도 함께 측정하였다. 결과: 섬유주세포에서 베바시주맙과 라니비주맙은 eNOS mRNA의 발현과 일산화질소의 생성을 감소시켰으며(p＜0.05), eNOS의 발현정도와 일산화질소 생성 정도에서 베바시주맙과 라니비주맙은 유의한 차이를 보이지 않았다. 결론: 섬유주세포에서 베바시주맙과 라니비주맙은 eNOS의 발현을 감소시켰으며, 그 정도에 있어서는 두 약제에서 차이를 나타내지않았다.
Abstract
Purpose: To compare the effects of bevacizumab and ranibizumab on the expression of eNOS in cultured human trabecularmeshwork cells (HTMC). Methods: Primarily cultured HTMC were exposed to 0.5 mg/mL bevacizumab and ranibizumab using 1% serum-containing mediafor 30 minutes. Expression of eNOS mRNA was assessed with RT-PCR. Additionally, after exposure to 20 ng/mL of vascularendothelial growth factor (VEGF) and 0.5 mg/mL bevacizumab and ranibizumab, the production of nitric oxide was assessedwith Griess assay. Results: VEGF increased the production of nitric oxide in HTMC. Bevacizumab and ranibizumab decreased the expression ofeNOS mRNA and production of nitric oxide (p < 0.05) in HTMC. The decrease in eNOS mRNA expression and production of nitricoxide was not significant between bevacizumab and ranibizumab (p > 0.05). Conclusions: In HTMC, both bevacizumab and ranibizumab decreased the expression of eNOS mRNA with no significant differenceobserved between the two drugs.
참고문헌 (25)
- Ferrara N, "The biology of vascular endothelial growth factor", Endocrine Rev, 18, pp.4~25 (1997)
- Bouloumié A, "Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells", Cardiovasc Res, 41, pp.773~780 (1999)
- Dulak J, "Nitric oxide induces the synthesis of vascular endothelial growth factor by rat vascular smooth muscle cells", Arteioscler Thromb Vasc Biol, 20, pp.659~666 (2000)
- Good TJ, "Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents", Br J Ophthalmol, 95, pp.1111~1114 (2011)
- Nathanson JA, "Identification of an extensive system of nitric oxide-producing cells in the ciliary muscle and outflow pathway of the human eye", Invest Ophthalmol Vis Sci, 36, pp.1765~1773 (1995)
- Geyer O, "Nitric oxide synthase activity in tissues of the bovine eye", Graefes Arch Clin Exp Ophthalmol, 235, pp.786~793 (1997)
- Meyer P, "Localization of nitric oxide synthase isoforms in porcine ocular tissues", Curr Eye Res, 18, pp.375~380 (1999)
- Wiederholt M, "Relaxation of trabecular meshwork and ciliary muscle by release of nitric oxide", Invest Ophthalmol Vis Sci, 35, pp.2515~2520 (1994)
- Behar-Cohen FF, "Decreased intraocular pressure induced by nitric oxide donors is correlated to nitrite production in the rabbit eye", Invest Ophthalmol Vis Sci, 37, pp.1711~1715 (1996)
- Nathanson JA, "Alterations of ocular nitric oxide synthase in human glaucoma", Invest Ophthalmol Vis Sci, 36, pp.1774~1784 (1995)
- nitrate in biological fluids, "Anal Biochem", 1982, 131~138
- Polansky JR, "Human trabecular cells. I. Establishment in tissue culture and growth characteristics", Invest Ophthalmol Vis Sci, 18, pp.1043~1049 (1979)
- Alvarado JA, "Human trabecular cells. II. Growth pattern and ultrastructural characteristics", Invest Ophthalmol Vis Sci, 23, pp.464~478 (1982)
- Wang H, "Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of flt-1", Circ Res, 83, pp.832~840 (1998)
- Xia P, "Characterization of vascular endothelial growth factor’s effect on the activation of protein kinase C, its isoforms, and endothelial cell growth", J Clin Invest, 98, pp.2018~2026 (1996)
- 윤숙현, "섬유주세포에서 니트로글리세린에 의한 일산화질소의 생성경로에 관한 연구", 대한안과학회지, 54(9), pp.1429~1434 (2013), 대한안과학회
- Spitzer MS, "Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen)and ranibizumab (Lucentis) on different ocular cells", Graefes Arch Clin Exp Ophthalmol, 245, pp.1837~1842 (2007)
- Kahook MY, "In vitro effects of antivascular endothelial growth factors on cultured human trabecular meshwork cells", J Glaucoma, 19, pp.437~441 (2010)
- 김신후, "베바시주맙이 섬유주세포의 생존과 일산화질소의 생성에 미치는 영향", 대한안과학회지, 50(9), pp.1404~1408 (2009), 대한안과학회
- Kernt M, "Bevacizumab is not toxic to human anterior- and posterior-segment cultured cells", Ophthalmologe, 104, pp.965~971 (2007)
- Kahook MY, "Sustained elevation of intraocular pressure associated with intravitreal bevacizumab injections", Ophthalmic Surg Lasers Imaging, 40, pp.293~295 (2009)
- Bakri SJ, "Persistent ocular hypertension following intravitreal ranibizumab", Graefes Arch Clin Exp Ophthalmol, 246, pp.955~958 (2008)
- Ladas JG, "Relationship between aqueous humor protein level and outflow facility in patients with uveitis", Invest Ophthalmol Vis Sci, 42, pp.2584~2588 (2001)
- Schuman JS, "Nitrovasodilator effects on intraocular pressure and outflow facility in monkeys", Exp Eye Res, 58, pp.99~105 (1994)
- Wang RF, "Effect of the topical application of nitroglycerin on intraocular pressure in normal and glaucomatous monkeys", Exp Eye Res, 60, pp.337~339 (1995)